DiaMedica Therapeutics Inc (DMAC) (Q3 2026) Earnings Call Highlights: REMEDI 2 Interim Analysis ...
DiaMedica Therapeutics Inc (DMAC) reached its 200th REMEDI 2 stroke trial participant, completed FGR cohort enrollment, and secured EMA authorization for preeclampsia while reporting a $11.3 million Related Stocks: DMAC ,